CBL anticorps (AA 470-766) (FITC)

N° du produit ABIN7975057

L’anticorps anti-CBL Polyclonal Lapin est utilisé pour la détection de CBL dans des échantillons de Humain, Souris et Rat. Il a été validé pour FACS.

Aperçu rapide pour CBL anticorps (AA 470-766) (FITC) (ABIN7975057)

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CBL est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Détail du produit anti-CBL anticorps (FITC)

Épitope: AA 470-766

Fonction: Anti-CBL Antibody FITC Conjugated

Réactivité croisée (Details): No cross-reactivity with other proteins.

Purification: Immunogen affinity purified.

Immunogène: E.coli-derived human CBL recombinant protein (Position: M470-E766).

Isotype: IgG

Information d'application

Indications d'application: Flow Cytometry, Optimal dilutions should be determined by end users.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4, 0.02 % Sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: At -20°C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

Date de péremption: 12 months

Détails sur CBL

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Autre désignation: CBL

Sujet:

Background: CBL(Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes(E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Gene Full Name: Cbl proto-oncogene

ID gène: 867

UniProt: P22681

Pathways: TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals